This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009; 6:519-27.10.1038/nrclinonc.2009.11119636327NormannoNTejparSMorgilloFDe LucaAVan CutsemECiardielloF.Implications for KRAS status and EGFR-targeted therapies in metastatic CRCNat Rev Clin Oncol.2009651927Open DOISearch in Google Scholar
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2011; 30: 3570-7.TejparSCelikISchlichtingMSartoriusUBokemeyerCVan CutsemE.Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximabJ Clin Oncol.2011303570710.1200/JCO.2012.42.2592Search in Google Scholar
Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011; 50:307-12.2130564010.1002/gcc.20854VaughnCPZobellSDFurtadoLVBakerCLSamowitzWS.Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancerGenes Chromosomes Cancer.20115030712Search in Google Scholar
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Medicine. 2008; 358:1160-74.10.1056/NEJMra0707704CiardielloFTortoraG.EGFR antagonists in cancer treatmentN Engl J Medicine.2008358116074Open DOISearch in Google Scholar
Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure. 2007; 15:1618-29.10.1016/j.str.2007.10.01118073111BuhrmanGWinkGMattosC.Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of RafStructure.200715161829Open DOISearch in Google Scholar
Feig LA, Cooper GM. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol. 1988; 8:2472-8.304317810.1128/MCB.8.6.2472FeigLACooperGM.Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteinsMol Cell Biol.1988824728Search in Google Scholar
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Brit J Cancer. 2009; 101: 715-21.10.1038/sj.bjc.6605177LoupakisFRuzzoACremoliniCVincenziBSalvatoreLSantiniDKRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBrit J Cancer.200910171521Open DOISearch in Google Scholar
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27:5931-7.1988454910.1200/JCO.2009.22.4295RichmanSDSeymourMTChambersPElliottFDalyCLMeadeAMKRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trialJ Clin Oncol.20092759317Search in Google Scholar
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-17.10.1056/NEJMoa080501919339720Van CutsemEKohneCHHitreEZaluskiJChang ChienCRMakhsonACetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med.2009360140817Open DOISearch in Google Scholar
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48:1466-75.2244602210.1016/j.ejca.2012.02.057BokemeyerCVan CutsemERougierPCiardielloFHeegerSSchlichtingMAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trialsEur J Cancer.201248146675Search in Google Scholar
Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci. 2013; 104: 473-80.2329831310.1111/cas.12098HongYSKimHJParkSJKimKPLeeJLParkJHSecond-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRASCancer Sci.201310447380Search in Google Scholar
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med. 2004; 351: 337-45.10.1056/NEJMoa033025CunninghamDHumbletYSienaSKhayatDBleibergHSantoroACetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Eng J Med.200435133745Open DOISearch in Google Scholar
Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010; 16:262-72.10.1097/PPO.0b013e3181e0773820526105WilsonPMLabonteMJLenzHJ.Molecular markers in the treatment of metastatic colorectal cancerCancer J.20101626272Open DOISearch in Google Scholar
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-12.1900132010.1200/JCO.2008.18.0786Di NicolantonioFMartiniMMolinariFSartore-BianchiAArenaSSalettiPWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancerJ Clin Oncol.200826570512Search in Google Scholar
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27:5924-30.10.1200/JCO.2008.21.679619884556Laurent-PuigPCayreAManceauGBucEBachetJBLecomteTAnalysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancerJ Clin Oncol.200927592430Open DOISearch in Google Scholar
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27:1477-84.1923763310.1200/JCO.2008.18.6544OginoSNoshoKKirknerGJShimaKIraharaNKureSPIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancerJ Clin Oncol.200927147784Search in Google Scholar
Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009; 20:84-90.18669866PerroneFLampisAOrsenigoMDi BartolomeoMGevorgyanALosaMPI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsAnn Oncol.200920849010.1093/annonc/mdn541Search in Google Scholar
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69:1851-7.10.1158/0008-5472.CAN-08-246619223544Sartore-BianchiAMartiniMMolinariFVeroneseSNichelattiMArtaleSPIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodiesCancer Res.20096918517Open DOISearch in Google Scholar
Hatzaki A, Razi E, Anagnostopoulou K, Iliadis K, Kodaxis A, Papaioannou D, et al. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes. 2001; 15:243-7.10.1006/mcpr.2001.036711735295HatzakiARaziEAnagnostopoulouKIliadisKKodaxisAPapaioannouDA modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patientsMol Cell Probes.2001152437Open DOISearch in Google Scholar
Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist’s perspective. J Clin Pathol. 2012; 65: 940-4.10.1136/jclinpath-2012-20077322872705MalapelleUBellevicineCSalatielloMde LucaCRispoERiccioPSanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist’s perspectiveJ Clin Pathol.2012659404Open DOISearch in Google Scholar
Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Brit J Cancer. 2012; 107: 626-31.10.1038/bjc.2012.275MalapelleUCarlomagnoCSalatielloMDe StefanoADe LucaCBiancoRKRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancerBrit J Cancer.201210762631Open DOISearch in Google Scholar
Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009; 4:e7746.1988847710.1371/journal.pone.0007746KotoulaVCharalambousEBiesmansBMalousiAVrettouEFountzilasGTargeted KRAS mutation assessment on patient tumor histologic material in real time diagnosticsPLoS One20094e7746Search in Google Scholar
Morlan J, Baker J, Sinicropi D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One. 2009; 4:e4584.10.1371/journal.pone.000458419240792MorlanJBakerJSinicropiD.Mutation detection by real-time PCR: a simple, robust and highly selective methodPLoS One20094e4584Open DOISearch in Google Scholar
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7:413-21.1604931410.1016/S1525-1578(10)60571-5OginoSKawasakiTBrahmandamMYanLCantorMNamgyalCSensitive sequencing method for KRAS mutation detection by PyrosequencingJ Mol Diagn.2005741321Search in Google Scholar
Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007; 203:489-97.1762941910.1016/j.prp.2007.06.001PoehlmannAKuesterDMeyerFLippertHRoessnerASchneider-StockR.K-ras mutation detection in colorectal cancer using the Pyrosequencing techniquePathol Res Pract.200720348997Search in Google Scholar
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304:1812-20.2097825910.1001/jama.2010.1535De RoockWJonkerDJDi NicolantonioFSartore-BianchiATuDSienaSAssociation of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabJAMA.2010304181220Search in Google Scholar
